Brad Pick Highlights PPTA’s Insights on Plasma Therapies for Trauma, Surgery and Chronic Illnesses
Brad Pick, Senior Director Global External Communications at Grifols, shared a post by Plasma Protein Therapeutics Association (PPTA) on LinkedIn:
”What many don’t realize is that plasma therapeutics treat more than rare and chronic diseases. They have a vital role in treating everyday medical situations such as trauma and major surgery. That’s something all of us can relate to.”
Quoting Plasma Protein Therapeutics Association (PPTA)‘s post:
”Using specialized techniques, pooled plasma is separated and purified, and each protein undergoes advanced processes for therapeutic safety.
These manufacturing steps lead to plasma-derived medicines, such as albumin, immunoglobulins, coagulation factors, C1 esterase inhibitors, and Alpha-1 proteinase inhibitors.
These plasma-derived medicines are used to treat a range of conditions, from immunodeficiencies to blood clotting disorders, highlighting the critical role plasma proteins play in a variety of conditions – more of which are being discovered every day.
Learn more about the journey of plasma-derived medicines on our YouTube channel.”
See the Plasma Protein Therapeutics Association (PPTA) post here.
Stay updated with Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia